Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2003 1
2008 2
2009 2
2010 2
2011 2
2012 2
2013 1
2014 1
2016 1
2017 1
2018 2
2019 1
2020 2
2021 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Wichmann J, Rynn C, Friess T, Petrig-Schaffland J, Kornacker M, Handl C, Emmenegger J, Eckmann J, Herting F, Frances N, Hunziker D, Krummenacher D, Rüttinger D, Ribeiro A, Bacac M, Brigo A, Hewings DS, Dummer R, Levesque MP, Schnetzler G, Martoglio B, Bischoff JR, Pettazzoni P. Wichmann J, et al. Among authors: frances n. Clin Cancer Res. 2022 Feb 15;28(4):770-780. doi: 10.1158/1078-0432.CCR-21-2761. Clin Cancer Res. 2022. PMID: 34782366
PKPD modeling of acquired resistance to anti-cancer drug treatment.
Eigenmann MJ, Frances N, Lavé T, Walz AC. Eigenmann MJ, et al. Among authors: frances n. J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):617-630. doi: 10.1007/s10928-017-9553-x. Epub 2017 Oct 31. J Pharmacokinet Pharmacodyn. 2017. PMID: 29090407 Free PMC article.
Progress in strategies for dosage regimen individualization.
Marouani H, Woloch C, Benay S, Frances N, Iliadis A. Marouani H, et al. Among authors: frances n. Curr Top Med Chem. 2012;12(15):1669-77. doi: 10.2174/156802612803531315. Curr Top Med Chem. 2012. PMID: 22978335
A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
Sánchez J, Claus C, Albrecht R, Gaillard BC, Marinho J, McIntyre C, Tanos T, Boehnke A, Friberg LE, Jönsson S, Frances N. Sánchez J, et al. Among authors: frances n. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1804-1818. doi: 10.1002/psp4.13065. Epub 2023 Nov 15. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37964753 Free PMC article.
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling.
Van De Vyver AJ, Weinzierl T, Eigenmann MJ, Frances N, Herter S, Buser RB, Somandin J, Diggelmann S, Limani F, Lehr T, Bacac M, Walz AC. Van De Vyver AJ, et al. Among authors: frances n. Mol Cancer Ther. 2021 Feb;20(2):357-366. doi: 10.1158/1535-7163.MCT-20-0269. Epub 2020 Dec 9. Mol Cancer Ther. 2021. PMID: 33298591
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.
Sánchez J, Nicolini V, Fahrni L, Waldhauer I, Walz AC, Jamois C, Fowler S, Simon S, Klein C, Umaña P, Friberg LE, Frances N. Sánchez J, et al. Among authors: frances n. AAPS J. 2023 Apr 1;25(3):34. doi: 10.1208/s12248-023-00802-9. AAPS J. 2023. PMID: 37002450 No abstract available.
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non-small cell lung cancer patients.
Ojara FW, Henrich A, Frances N, Nassar YM, Huisinga W, Hartung N, Geiger K, Holdenrieder S, Joerger M, Kloft C. Ojara FW, et al. Among authors: frances n. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1714-1725. doi: 10.1002/psp4.12937. Epub 2023 Feb 27. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36782356 Free PMC article.
23 results